(Q47679500)

4 February 2018

title

Pathophysiology, evaluation, and management of sleep disorders in the mucopolysaccharidoses. (English)

1 reference

4 February 2018

1 reference

David M Rapoport

1

1 reference

4 February 2018

John J Mitchell

series ordinal

2

1 reference

4 February 2018

publication date

25 August 2017

1 reference

4 February 2018

Molecular Genetics and Metabolism

published in

1 reference

4 February 2018

volume

122S

1 reference

4 February 2018

page(s)

49-54

1 reference

4 February 2018

Overview of the mucopolysaccharidoses

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Prevalence of obstructive sleep apnea in patients with mucopolysaccharidosis types I, II, and VI in a reference center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Respiratory complications of mucopolysaccharide storage disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Disordered breathing during sleep in patients with mucopolysaccharidoses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Sleep abnormalities in untreated patients with mucopolysaccharidosis type VI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Assessment of sleep in children with mucopolysaccharidosis type III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Severe type Hunter's syndrome. Polysomnographic and neuropathological study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Respiratory and sleep disorders in mucopolysaccharidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Respiratory manifestations in mucopolysaccharidoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Otorhinolaryngological manifestations of the mucopolysaccharidoses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Mucopolysaccharidosis: Otolaryngologic findings, obstructive sleep apnea and accumulation of glucosaminoglycans in lymphatic tissue of the upper airway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Lung volume and continuous positive airway pressure requirements in obstructive sleep apnea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Obstructive airway in Morquio A syndrome, the past, the present and the future.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Home sleep study characteristics in patients with mucopolysaccharidosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Polysomnographic characteristics in patients with mucopolysaccharidoses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Obesity hypoventilation syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Relationship of sleep to pulmonary function in mucopolysaccharidosis II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Effects of varying approaches for identifying respiratory disturbances on sleep apnea assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Patterns and predictors of sleep disordered breathing in primary myopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Non-invasive pulmonary function test on Morquio patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Comparison of treatment modalities in syndromic children with obstructive sleep apnea--a randomized cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Surgical Reconstruction for Severe Tracheal Obstruction in Morquio A Syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Successful use of nasal-CPAP for obstructive sleep apnea in Hunter syndrome with diffuse airway involvement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Hunter's syndrome and associated sleep apnoea cured by CPAP and surgery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Hurler's syndrome with cor pulmonale secondary to obstructive sleep apnoea treated by continuous positive airway pressure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Resolution of obstructive sleep apnea in Hurler syndrome after bone marrow transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Enzyme replacement therapy for mucopolysaccharidosis VI—experience in Taiwan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Obstructive sleep apnea syndrome after hematopoietic stem cell transplantation in children with mucopolysaccharidosis type I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Sleep problems in children with Sanfilippo syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Natural history of Sanfilippo syndrome type A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Sleep disturbance in Sanfilippo syndrome: a parental questionnaire study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Challenging symptoms in children with rare life-limiting conditions: findings from a prospective diary and interview study with families.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Actigraphic investigation of circadian rhythm functioning and activity levels in children with mucopolysaccharidosis type III (Sanfilippo syndrome)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Impairment of the melatonin rhythm in children with Sanfilippo syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Neuroanatomical and Electroencephalographic Correlations in Sanfilippo Syndrome, Type A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Sleep disorders in Sanfilippo syndrome: a polygraphic study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Sleep disturbance in mucopolysaccharidosis type III (Sanfilippo syndrome): a survey of managing clinicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Practical management of behavioral problems in mucopolysaccharidoses disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Epilepsy in mucopolysaccharidosis disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

Nocturnal frontal lobe epilepsy in mucopolysaccharidosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.08.008

10.1016/J.YMGME.2017.08.008

7 January 2021

Identifiers

DOI

1 reference

4 February 2018

PubMed ID

28964643

1 reference

4 February 2018